Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?

Core Viewpoint - ADMA Biologics (ADMA) shows significant upside potential with a mean price target of $27.33, indicating a 51.8$18.01 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.04, where the lowest estimate of$25 suggests a 38.8% increase, and the highest estimate of $32 indicates a potential surge of 77.7% [2] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [8] Earnings Estimates and Analyst Sentiment - Analysts exhibit growing optimism about ADMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.2%, with one estimate moving higher and no negative revisions [11] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the stock's potential upside [12]